» Articles » PMID: 29541759

Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction

Overview
Journal JAMA Cardiol
Date 2018 Mar 16
PMID 29541759
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Heart failure with preserved ejection fraction (HFpEF) is highly prevalent, yet there are no specific therapies, possibly due to phenotypic heterogeneity. The development of pulmonary hypertension (PH) in patients with HFpEF is considered a high-risk phenotype in need of targeted therapies, but there have been limited hemodynamic and outcomes data.

Objective: To identify the hemodynamic characteristics and outcomes of PH-HFpEF.

Design, Setting, And Participants: Cohort study of participants who had a right heart catheterization from January 2005 to September 2012 (median [interquartile range] follow-up time, 1578 [554-2513] days) were analyzed. Hemodynamic catheterization data was linked to the clinical data repository of all inpatient and outpatient encounters across a health system. Single tertiary referral center for heart failure and PH within a large health care network using a common clinical data repository was studied. There were 19 262 procedures in 10 023 participants.

Exposures: Participants were classified as having no PH, precapillary PH, or PH in the setting of left heart disease (reduced or preserved ejection fraction). Pulmonary hypertension associated with HFpEF was defined as mean pulmonary artery pressure of 25 mm Hg or more, pulmonary artery wedge pressure of 15 mm Hg or more, and left ventricular ejection fraction of 45% or more. Pulmonary hypertension severity was quantified by the hemodynamic parameters transpulmonary gradient, pulmonary vascular resistance, and diastolic pulmonary gradient.

Main Outcomes And Measures: The primary outcome was time to all-cause mortality. Secondary outcomes were time to acute hospitalization and cardiovascular hospitalization.

Results: The mean (SD) of all study individuals was 65 (38) years. Of 10 023 individuals, 2587 (25.8%) had PH-HFpEF. Mortality was 23.6% at 1 year and 48.2% at 5 years. Cardiac hospitalizations occurred in 28.1% at 1 year and 47.4% at 5 years. The frequency of precapillary PH using clinically defined cut-offs for transpulmonary gradient (>12 mm Hg), pulmonary vascular resistance (3 Woods units), and diastolic pulmonary gradient (≥7 mm Hg) were 12.6%, 8.8%, and 3.5%, respectively. Transpulmonary gradient, pulmonary vascular resistance, and diastolic pressure gradient were predictive of mortality and cardiac hospitalizations.

Conclusions And Relevance: In a large cohort referred for invasive hemodynamic assessment, PH-HFpEF was common. Transpulmonary gradient, pulmonary vascular resistance, and diastolic pulmonary gradient are all associated with mortality and cardiac hospitalizations.

Citing Articles

Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study.

Shah S, Bonderman D, Borlaug B, Cleland J, Lack G, Lu W Circ Heart Fail. 2025; :e011381.

PMID: 40066571 PMC: 11905905. DOI: 10.1161/CIRCHEARTFAILURE.123.011381.


Staging Heart Failure with Preserved Ejection Fraction by Assessing Cardiac Chamber Involvement.

Shchendrygina A, Giverts I, Tokmakova M, Kharchenko E, Vlasova A, Rogova A Eur Cardiol. 2024; 19:e20.

PMID: 39588252 PMC: 11588106. DOI: 10.15420/ecr.2024.31.


Ventricular interdependent phenotype of mixed Cpc-pulmonary hypertension and HFpEF with normal left atrium: Impact on CPET metrics and clinical outcomes.

Zampierollo-Jaramillo G, Abed A, El Shaer A, Garcia-Arango M, Chen Y, Tehrani B Pulm Circ. 2024; 14(4):e12449.

PMID: 39398323 PMC: 11467789. DOI: 10.1002/pul2.12449.


Heart failure with preserved ejection fraction.

Hamo C, DeJong C, Hartshorne-Evans N, Lund L, Shah S, Solomon S Nat Rev Dis Primers. 2024; 10(1):55.

PMID: 39143132 DOI: 10.1038/s41572-024-00540-y.


Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study.

Fauvel C, Damy T, Berthelot E, Bauer F, Eicher J, de Groote P Eur Heart J. 2024; 45(35):3274-3288.

PMID: 39056467 PMC: 11400736. DOI: 10.1093/eurheartj/ehae467.


References
1.
Tampakakis E, Leary P, Selby V, De Marco T, Cappola T, Felker G . The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail. 2014; 3(1):9-16. PMC: 4289416. DOI: 10.1016/j.jchf.2014.07.010. View

2.
Maron B, Hess E, Maddox T, Opotowsky A, Tedford R, Lahm T . Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation. 2016; 133(13):1240-8. PMC: 4811678. DOI: 10.1161/CIRCULATIONAHA.115.020207. View

3.
Redfield M, Chen H, Borlaug B, Semigran M, Lee K, Lewis G . Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309(12):1268-77. PMC: 3835156. DOI: 10.1001/jama.2013.2024. View

4.
Opitz C, Hoeper M, Gibbs J, Kaemmerer H, Pepke-Zaba J, Coghlan J . Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum. J Am Coll Cardiol. 2016; 68(4):368-78. DOI: 10.1016/j.jacc.2016.05.047. View

5.
Beddhu S, Bruns F, Saul M, Seddon P, Zeidel M . A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med. 2000; 108(8):609-13. DOI: 10.1016/s0002-9343(00)00371-5. View